{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ESPR",
  "name": "Esperion Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/ESPR/",
  "json_url": "https://frontierpicks.com/dossiers/ESPR.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Resolved and off the tape. ARCHIMED's take-private closed 2026-07-13 at $3.16 cash plus a non-tradeable CVR of up to $100M; Nasdaq was asked to file Form 25 the same day and reporting duties are being suspended by Form 15. The early-August Q2 window passed with no filing. Last listed close $3.18 on 2026-07-10; only a private milestone tail running to 2030 remains.",
  "invalidation_trigger": "A daily close below $3.16 can no longer print: ESPR was cancelled into cash and the Form 25 delisting request was filed 2026-07-13; final listed close was $3.18 on 2026-07-10. Only a new Nasdaq/NYSE listing of an Esperion equity security restores a gradeable tape.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Esperion common stock ceased trading and was delisted from Nasdaq on 2026-07-13; any live ESPR quote in a data feed is stale legacy data.",
    "The CVR is non-transferable and unlisted: up to $100M aggregate, no public market, no observable mark.",
    "Esperion notified Nasdaq on 2026-07-13 to file Form 25; the company stated it intends to file Form 15 to suspend Exchange Act reporting.",
    "No public Q2 2026 print exists: the customary early-August reporting slot passed with no filing.",
    "Milestone windows run through calendar 2027 (bempedoic acid) and 2030 (bumetanide); outcomes may never appear in a public filing."
  ],
  "body_markdown": "## Current Thesis\nSix weeks past the closing and nothing has reopened. ARCHIMED completed its take-private of Esperion on 2026-07-13; per the buyer's release, \"Esperion common stock has ceased trading and is no longer listed on the NASDAQ Stock Market.\" The same-day 8-K records that Esperion notified Nasdaq of the merger's consummation and requested Nasdaq file a Form 25 to delist and deregister the common stock under Section 12(b), with the company intending to file a Form 15 to suspend its Exchange Act Section 13 and 15(d) reporting duties. Holders received $3.16 per share in cash plus a non-transferable right to contingent milestone payments of up to $100M in aggregate. The last completed daily bar is $3.18 on 2026-07-10; there are no bars after it. The narrative leg an investor was buying — an arb spread closing into a fixed cash number — was paid out. The narrative is **dead**, dated to 2026-07-13. Dead by completion, not by failure: the deal worked and the structure the tape traded on was dismantled by the same event.\n\n## Bull Case\n- on 2026-07-08 by 135,326,793 for, 22,750,628 against, 496,194 abstaining.\n- Cash paid at $3.16 per share, described by the buyer on 2026-07-13 as a 58% premium to the 2026-04-30 close — the pre-announcement reference.\n- Financing held: unitranche debt from Pharmakon Advisors, equity through ARCHIMED's MED Platform II, per the 2026-07-13 completion release. Headline equity value up to roughly $1.1B (€962M) fully diluted assuming full milestone achievement.\n- The operating business was still compounding into the bid: Q1 2026 revenue $80.1M, +23% YoY, split $43.4M product and $36.7M collaboration, with net loss narrowing to $25.2M from $40.5M a year earlier.\n- The franchise continues to sell outside the US under partner economics: Daiichi Sankyo's Q1 FY2026 results (quarter ended 2026-06-30) put EU Specialty Business revenue at ¥74.7B, attributed to Lixiana and Nilemdo/Nustendi.\n\n## Bear Case\n- There is no instrument. The common stock was cancelled into cash on 2026-07-13, and the Form 25 request filed that day removes both the listing and the Section 12(b) registration. Any screen showing an ESPR last price is carrying data from on or before 2026-07-10.\n- The Q2 2026 print that would normally have landed in the first half of August 2026 did not occur, and as of 2026-08-22 no Q2 revenue, cash or ENBUMYST launch figure exists in any public filing. That window came and went with nothing in it.\n- The CVR does not trade, is not listed and has no rights-agent quotation, so the residual tail cannot be bought, sold or marked against an observable price.\n- The disclosed milestone math is demanding: the $40M tranche requires bempedoic-acid US net sales above $350M in calendar 2027, against Q1 2026 US product revenue of $43.4M; the $60M tranche requires ENBUMYST/bumetanide US net sales of at least $160M in a single year through 2030, from a product only beginning its commercial ramp.\n- Daiichi Sankyo's EU segment number is ex-US and blended with Lixiana, so it cannot grade a US-net-sales milestone. It is a demand signal for the molecule, not a readout on the CVR.\n- The RSI(14) of 61.5 on the final bar reflects a tape pinned two cents above fixed cash terms, and the $4.08 52-week high predates the 2026-05-01 announcement and was never reachable under those terms.\n\n## Setup & Price Structure\n- One gap did the work: the 2026-05-01 announcement lifted the stock from roughly $2 into the low-$3s, and the tape then sat within pennies of the $3.16 cash number for ten weeks.\n- Final observable pricing: last completed daily close $3.18 on 2026-07-10, a three-month price change of +46.5%, 22.1% below the $4.08 52-week high. No bar prints after 2026-07-10.\n- Crowding and positioning evidence is now unobservable by construction, and that absence is the datapoint: with Section 16 reporting terminated there is no further insider Form 4 flow, no updated short-interest series, no float or borrow data, and no scheduled earnings date to crowd into. Retail-sentiment coverage on the name stopped at the 2026-05-26 EAS Congress data presentation; the last two headlines in the feed are both pre-close, dated 2026-05-13 and 2026-05-26.\n- Any \"quote\" a screener still returns for the symbol is legacy data. A symbol-stitched historical series is now at risk of splicing an unrelated issuer if Nasdaq or NYSE reassigns ESPR.\n\n## Catalyst Calendar (next 30 days)\n\n- **None between 2026-08-22 and 2026-09-21.** There is no scheduled print, no PDUFA, no listing event, and no public CVR reporting obligation inside the window.\n- **~2026-10-30 (est.):** Daiichi Sankyo Q2 FY2026 results — the next public window on ex-US bempedoic-acid demand, reported at segment level rather than by product.\n- **2027-12-31:** close of the calendar-2027 measurement window for the $40M bempedoic-acid CVR milestone (US net sales above $350M).\n- **2030-12-31:** final year of the window for the $60M ENBUMYST/bumetanide milestone (US net sales at or above $160M in any single year).\n\n## Elapsed catalysts\n\n- **~2026-08-05 (est.), elapsed:** the customary early-August Q2 reporting slot passed without a filing, consistent with the Form 15 suspension of reporting duties. *(passed 21d ago)*\n\n## What Would Change Our Mind\nOnly one thing restores a gradeable read here: a new Nasdaq or NYSE listing notice for an Esperion equity security, or an exchange reassigning the ESPR symbol to a different issuer — the second would corrupt any series stitched by symbol and should be checked against the new-listing notice before any historical comparison is made. Absent that, a daily close below $3.16 can no longer print, because the security was cancelled into cash and the Form 25 request went in on 2026-07-13; the final listed close was $3.18 on 2026-07-10. On the residual tail, the datapoint that would move the read is any public disclosure of Esperion US net sales for NEXLETOL/NEXLIZET or ENBUMYST for full-year 2027 — a CVR holder communication, an ARCHIMED portfolio disclosure or a partner filing that breaks out the US line. If calendar-2027 US bempedoic-acid net sales are disclosed above $350M, the $40M tranche is in the money; if no such disclosure ever surfaces, the tail is unvaluable from public information and should be treated as such.\n\n## Correlation Notes\n- The name no longer tracks XBI or the small-cap biotech tape. From 2026-05-01 to 2026-07-10 it traded on deal-completion probability, not sector beta, and after 2026-07-13 it does not trade at all.\n- The only public proxy for the underlying molecule is Daiichi Sankyo (TSE:4568), whose Q1 FY2026 EU Specialty Business line of ¥74.7B is credited to Lixiana and Nilemdo/Nustendi jointly. Geography and aggregation both cut against using it as a milestone proxy.\n- The completed financing — Pharmakon unitranche into an ARCHIMED MED Platform II equity cheque — is a live datapoint on sponsor appetite for commercial-stage cardiometabolic assets, and reads across to the take-private cohort of unprofitable US biotechs with launched products rather than to Esperion itself.\n- For screens and backtests, the practical exposure is data hygiene: a cancelled security with a stale last price will show as a low-volatility, positive-momentum holding indefinitely unless the 2026-07-13 delisting is written into the security master.",
  "first_seen": "2026-05-14",
  "last_analyzed": "2026-08-22T08:31:18+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}